ALFA Finder| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 240.0 | 223.9 | 193.0 |
| Other income | 4.2 | 4.3 | 4.7 |
| Total income | 244.2 | 228.3 | 197.7 |
| Profit before exceptional items & tax | 67.6 | 63.9 | 50.2 |
| Profit before tax | 68.3 | 64.4 | 50.5 |
| Net profit | 51.3 | 48.7 | 38.3 |
| Operating margin | 28.0% | 28.2% | 25.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +33.90% |
|---|---|
| Net profit, quarter on quarter | +5.30% |
| Revenue, year on year | +24.40% |
| Operating profit, year on year | +40.20% |
| Operating profit, quarter on quarter | +6.10% |
BSE results filing, NSE: THYROCARE. Figures extracted from the filing.
Thyrocare Technologies Ltd: key numbers
- Share price
- ₹490.80
- Market cap
- ₹7,821 Cr
- Revenue (annual)
- ₹829.0 Cr
- Net profit (annual)
- ₹163.0 Cr
- P/E (TTM)
- 54.2×Sector 54.5×
- Promoter holding
- 51.02%-9.90% QoQ
- FII holding
- 9.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Thyrocare Technologies Ltd
All →Thyrocare Technologies Other Announcement
Designated person Rahul Guha bought 2,121 Thyrocare shares via market purchase on November 6, 2026, worth ₹0.10 Crore. Post-trade holding is 200,859 shares.
- Value
- ₹0.10 Cr
Thyrocare Technologies Employee Stock Options
Thyrocare allotted 1,94,289 equity shares under its Employee Stock Option Scheme. The allotment lifts paid-up capital to Rs 159.36 crore.
Thyrocare Technologies Management Change
Thyrocare Technologies' Chief Scientific Officer, Dr. Preet Kaur, resigns effective November 6, 2026. The company is identifying a replacement and will disclose details later.
Thyrocare Technologies Other Announcement
Thyrocare disclosed NSE market purchases by an immediate relative and a KMP on 2 November 2026. Combined consideration is about Rs 0.11 Crore, with no promoter involved.
- Value
- ₹0.11 Cr
Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr
Thyrocare agreed to sell its entire stake in subsidiary Nueclear Healthcare to Trovera. The consideration is about Rs 141.40 Crore, including preference shares and cash.
- Value
- ₹141.4 Cr
Thyrocare Technologies Annual General Meeting
Thyrocare Technologies reported postal ballot voting results approving the purchase of land and building from, and divestment of its entire shareholding in, Nueclear Healthcare Limited.